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Abstract
The present opinion deals with the evaluation of the proposed increase of the currently authorised
maximum amounts of ferric sodium ethylenediaminetetraacetic acid (EDTA) as a novel food ingredient
used as a source of iron, and its extension of use in processed cereal-based foods and baby foods.
The applicant also provided information on two forms of ferric sodium EDTA, one previously assessed
by EFSA and a new one of ﬁner consistency. To support the proposed changes to the uses of ferric
sodium EDTA, the applicant proposed a revision of the current acceptable daily intake (ADI) for EDTA,
derived from that set for the food additive calcium disodium EDTA (E 385). The Panel conﬁrmed that
ferric sodium EDTA is a source from which iron is bioavailable. In assessing the safety of the proposed
revision to the existing speciﬁcations for the novel food ingredient ferric sodium EDTA, the Panel noted
that this would not discriminate between the previously evaluated substance and the one of ﬁner
consistency. In particular, the Panel noted that particle size was not one of the proposed parameters
for the revised speciﬁcations. The Panel noted that it was not possible to determine whether particles
of ferric sodium EDTA in the nano range were present in the product with ﬁner consistency in the solid
form. The toxicological data submitted did not add any new relevant information to the database on
which the current ADI for EDTA is based. Consequently, the Panel concluded that there was no sound
scientiﬁc justiﬁcation to increase the ADI for EDTA and hence increase the use levels of ferric sodium
EDTA or introduce additional uses as proposed by the applicant. The Panel recommended that
additional toxicological data should be provided to address the shortcomings in the available toxicity
database prior to the re-evaluation of calcium disodium EDTA (E 385).
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Summary
Following a request from the European Commission to the European Food Safety Authority (EFSA),
the Panel on Food Additives and Nutrient Sources added to Food (ANS) was asked to provide a scientiﬁc
opinion on the proposed changes to the current authorisation of ferric sodium ethylenediaminetetraacetic
acid (EDTA) as a novel food ingredient, used as a source of iron. Within the current application, it is
proposed to increase the maximum amounts of ferric sodium EDTA that can be added to foods for the
general population, food supplements in children, foods for special medical purposes and total diet
replacement for weight control. The applicant also proposes the inclusion of ferric sodium EDTA in the list
of substances permitted for use in processed cereal-based foods and baby foods.
In the dossier submitted by the applicant in support of the current application, it is reported that two
different products are being commercialised as ferric sodium EDTA: Ferrazone®, which was the subject
of the previous evaluation of ferric sodium EDTA by the ANS Panel, and Ferrazone XF®, a product of ﬁner
consistency obtained by adding an extra grinding step to the manufacturing process of Ferrazone®.
The applicant has submitted analytical results from three batches of Ferrazone XF® to demonstrate
compliance with the proposed update to the existing speciﬁcations. The Panel however noted that no
parameters have been proposed for the update of the speciﬁcations of ferric sodium EDTA with
respect to particle size which could be used for the discrimination between the two different products.
Furthermore, based on the analytical data provided, the Panel could not exclude the presence of
particles of ferric sodium EDTA in the nano-range in Ferrazone XF® in the solid form. The Panel further
noted that according to the applicant, there is no difference in the solubility in water of Ferrazone®
and Ferrazone XF®.
To support the proposed increase in the maximum amounts of ferric sodium EDTA in currently
authorised uses and to extend the use to processed cereal-based food and baby food, the applicant
proposed a revision of the current acceptable daily intake (ADI) for EDTA on the basis of newly
submitted toxicological data on other EDTA salts, previously not available for assessment by the Panel.
Based on the additional absorption, distribution, metabolism and excretion (ADME) studies provided
and on its previous assessment, the ANS Panel considered that, following oral ingestion, ferric sodium
EDTA would dissociate into its components, EDTA and iron in the gastrointestinal tract. EDTA is not
absorbed to a large extent and will be excreted in the faeces. Minor amounts of EDTA may be
absorbed but are not metabolised, and may be excreted unchanged in urine. Only a small proportion
of the dissociated iron is absorbed; the largest fraction is excreted in an insoluble form in the faeces.
The Panel further noted that the ADME studies assessed may be of limited relevance for the newly
proposed form of ferric sodium EDTA indicated by the applicant, i.e. Ferrazone XF®, since, due to its
reduced particle size, the product may have different characteristics with regard to ADME. With the
available data, the Panel was not in the position to draw conclusions on this matter.
In its previous opinion, the ANS Panel reviewed three subchronic studies in rats with dietary
exposure to ferric sodium EDTA. In the present dossier, the applicant submitted four additional
subchronic studies on EDTA salts other than ferric sodium EDTA. The Panel noted that the design and
reporting of some of these studies had limitations, and were not considered suitable for risk
assessment. The Panel further noted that these studies did not add any new relevant information to
the database available for the previous evaluation of ferric sodium EDTA.
The Panel considered that the two reproductive toxicity studies submitted in the dossier provided
insufﬁcient data to evaluate the reproductive toxicity of ferric sodium EDTA.
The Panel noted that the prenatal developmental study provided in the dossier was inadequate for
risk assessment but is nevertheless concerned about the effects of ferric sodium EDTA reported. The
Panel was also concerned about the adverse developmental effects of EDTA given in the diet seen in
other, albeit limited, studies available in the literature.
The Panel has estimated intake levels for iron and exposure to EDTA resulting from the new
proposed uses and use levels. The Panel noted that the exposure to EDTA for all population groups
from the new proposed uses will signiﬁcantly exceed the current ADI of 1.9 mg/kg body weight (bw)
per day at the mean and 95th percentile.
The Panel conﬁrmed that ferric sodium EDTA is a source from which iron is bioavailable.
In assessing the safety of the proposed revision to the existing speciﬁcations for the novel food
ingredient ferric sodium EDTA, the Panel noted that this would not discriminate between the previously
evaluated substance (marketed as Ferrazone®) and the one of ﬁner consistency (Ferrazone XF®)
produced by adding an extra grinding step to the manufacturing process. In particular the Panel noted
that particle size was not one of the proposed parameters for the revised speciﬁcations. The
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Panel noted that it was not possible to determine whether particles of ferric sodium EDTA in the nano-
range were present in solid Ferrazone XF®.
The Panel concluded that the exposure assessment based on the proposed extension of uses and
use levels would lead to the current ADI for EDTA being exceeded in all population groups at the mean
and 95th percentile.
Additionally, the Panel concluded that the toxicological data submitted by the applicant did not
provide any new relevant information to the database on which the current ADI was established.
Consequently, the Panel concluded that there was no basis to increase the ADI for EDTA and hence
increase the use levels of ferric sodium EDTA or introduce additional uses as proposed by the
applicant.
The Panel further noted that in accordance with Regulation (EU) No 257/2010, a full re-evaluation
of the safety of calcium disodium EDTA (E 385) as a food additive is to be performed by EFSA. In this
context, the full toxicological database for this substance will be reviewed including the basis for
establishing the ADI for EDTA. The Panel recommended that additional toxicological data should be
provided to address the shortcomings in the available toxicity database prior to the re-evaluation of
calcium disodium EDTA (E 385) as a food additive.
Ferric sodium EDTA
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1. Introduction
The present scientiﬁc opinion deals with the evaluation of proposed amendments to the existing
speciﬁcations and conditions of use of ferric sodium ethylenediaminetetraacetic acid (EDTA) currently
authorised as a novel food ingredient; the possible revision of the toxicological database on the basis
of which the currently applicable acceptable daily intake (ADI) for EDTA was set, and the evaluation of
ferric sodium EDTA as a proposed source of iron in processed cereal-based foods and baby foods.
In assessing the safety of a nutrient source which dissociates, the Panel evaluates the safety of all
products of that dissociation other than the nutrient. Therefore, the safety of iron itself, in terms of
amounts that may be consumed, and the consideration of iron as a nutrient are outside the remit of
this Panel.
1.1. Background and Terms of Reference as provided by the European
Commission
1.1.1. Background
The European Union legislation lists nutritional substances that may be used for nutritional
purposes in certain categories of foods as sources of certain nutrients.
The relevant Union legislative measures are:
• Regulation (EC) No 258/97 of the European Parliament and the Council concerning novel foods
and novel food ingredients.1
• Directive 2002/46/EC of the European Parliament and of the Council on the approximation of
the laws of the Member States relating to food supplements.2
• Regulation (EC) 1925/2006 on the addition of vitamins and mineral and of certain other
substances to foods.3
• Regulation (EU) No 609/2013 of the European Parliament and of the Council on food intended
for infants and young children, food for special medical purposes, and total diet replacement
for weight control.4
On 4 September 2006, the company AkzoNobel Chemicals GmbH made a request to the competent
authorities of the United Kingdom to place ferric sodium EDTA on the market as a novel food ingredient.
On 26 November 2009, following a request from the Commission, the Scientiﬁc Panel on Food
Additives and Nutrient Sources added to Food (ANS) adopted an opinion on the safety of ferric sodium
EDTA (EFSA ANS Panel, 2010). In the opinion, EFSA concluded that EDTA is of no safety concern as
long as the intake does not exceed 1.9 mg EDTA per kg bw per day.
On 14 June 2010, Commission Decision 2010/331/EU authorising the placing on the market of ferric
sodium EDTA as a novel food ingredient under Regulation (EC) No 258/97 was published.
On 14 November 2011, Commission Regulation (EU) No 1161/2011 was adopted to allow the use
of ferric sodium EDTA as a source of iron in food supplements, fortiﬁed foods and certain food for
particular nutritional uses.
On 26 July 2017, the company AkzoNobel Business Area Specialty Chemicals made a request to the
Commission to amend both Annexes I (speciﬁcations) and II (maximum amounts) to Commission
Decision 2010/331/EU authorising the placing on the market of ferric sodium EDTA as a novel food
ingredient under Regulation (EC) No 258/97, and Annex to Regulation (EU) No 609/2013 for ferric
sodium EDTA to be allowed for use as a source of iron also in processed cereal-based foods and baby
foods.
The request concerns the revision of speciﬁcations and the maximum use levels of ferric sodium
EDTA as an authorised source of iron in certain food categories as well as the authorisation to allow
use of ferric sodium EDTA as a source of iron in processed cereal-based foods and baby foods, based
on the new information provided by the applicant.
1 OJ L 43, 14.2.97, p. 1.
2 03 L 183, 12.7.2002, p. 5I.
3 01 L 404, 30.12.2006, p. 26.
4 OJ L 181, 29.6.2013, p. 35.
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1.1.2. Terms of Reference
In accordance with Article 29(1)(a) of Regulation (EC) No 178/20025, the European Commission
asks the European Food Safety Authority to:
• carry out the new assessment for ferric sodium EDTA as a novel food ingredient in the context
of Regulation (EC) No 258/97
• following the outcome of the novel food assessment, evaluate the safety of ferric sodium EDTA
when added for nutritional purposes as a source of iron to food for the general population
(including food supplements), total diet replacement for weight control, food for special
medical purposes and processed cereal-based foods and baby foods, and the bioavailability of
iron from this source, in the context of Directive 2002/46/EC, Regulation (EC) No 1925/2006
and Regulation (EU) No 609/2013.
1.2. Interpretation of the Terms of Reference
The Panel is requested to evaluate the safety of the proposed changes to the speciﬁcations of the
novel food ingredient ferric sodium EDTA. With the present dossier the applicant intends to cover two
different forms of ferric sodium EDTA: the previously assessed form, i.e. Ferrazone®, and a new form
with ﬁner consistency, i.e. Ferrazone XF®.
To address the evaluation of the safety of the proposed changes to the maximum amounts listed in
Annex II to Commission Decision 2010/331/EU and the proposed inclusion in the list of substances
permitted for use in processed cereal-based foods and baby foods, the Panel considered the
information provided by the applicant in the dossier, including new toxicological data submitted in
support of a revision of the current ADI for EDTA (see Section 1.3) and that were used as a basis to
set maximum amounts for the authorisation of the novel food ingredient ferric sodium EDTA. The
evaluation involved an assessment of ferric sodium EDTA and its constituents iron and EDTA.
1.3. Information on existing evaluations and authorisations
Ferric sodium EDTA is currently authorised as a novel food ingredient to be used in fortiﬁed foods,
dietetic foods, foods for speciﬁc groups (foods for special medical purposes, total diet replacement for
weight control, processed cereal-based foods and baby foods) and food supplements.
The safety of ferric sodium EDTA and the bioavailability of iron from this source added for
nutritional purposes to foods for the general population and to foods for particular nutritional uses
have been previously evaluated by EFSA (EFSA ANS Panel, 2010). In its 2010 opinion, the
Panel concluded that the use of ferric sodium EDTA for the proposed uses is of no safety concern as
long as the intake of EDTA does not exceed 1.9 mg EDTA/kg body weight (bw) per day.
The conclusions from the ANS Panel were similar to the conclusions reached by the Joint FAO/WHO
Expert Committee on Food Additives (JECFA) in 2007, when it had also evaluated the safety of sodium
iron EDTA as to its use for iron fortiﬁcation (JECFA, 2007). JECFA had established an ADI for EDTA of
1.9 mg EDTA/kg bw per day, based on the ADI of 2.5 mg/kg bw per day established for the food
additive calcium disodium EDTA by JECFA in 1974 (JECFA, 1974).
The ADI for EDTA established by JECFA in 1974 had been previously endorsed by the Scientiﬁc
Committee for Food (SCF) in 1977 and in 1990, when calcium disodium EDTA was evaluated for use as
an antioxidant food additive (SCF, 1977, 1990).
Currently, calcium disodium EDTA (E 385) is an authorised food additive in the European Union
(EU) according to Annex II and Annex III to Regulation (EC) No 1333/2008 on food additives. It is
permitted for use in several food categories, with maximum levels ranging from 75 to 250 mg calcium
disodium EDTA/kg. Currently, its re-evaluation as a food additive, as foreseen in Regulation (EC)
No 257/20106, is still ongoing.7
5 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general
principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in
matters of food safety. OJ L 31, 1.2.2002, p. 1–24.
6 Commission Regulation (EU) No 257/2010 of 25 March 2010 setting up a programme for the re-evaluation of approved food
additives in accordance with Regulation (EC) No 1333/2008 of the European Parliament and of the Council on food additives.
7 http://registerofquestions.efsa.europa.eu/roqFrontend/questionloader?question-EFSA-Q-2011-00643
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1.3.1. Iron
No Tolerable Upper Intake Level (UL) has been set for iron by EFSA (EFSA NDA Panel, 2004).
Adverse gastrointestinal effects have been reported after short-term ingestion of non-haem iron
preparations at doses of 50–60 mg/day, particularly if taken without food. The NDA Panel considered
that these adverse gastrointestinal effects were not a suitable basis to establish a UL for iron from all
sources. The NDA Panel also considered that a UL cannot be established for iron based on iron
overload, because there were inadequate data to enable the construction of reliable response curves
between intake, body burden, homoeostatic adaptations and adverse health effects, including
increased risk of chronic diseases such as cardiovascular disease, diabetes and cancer.
The NDA Panel has deﬁned dietary reference values for iron (EFSA NDA Panel, 2015) providing
Average Requirements and Population Reference Intake values that are summarised in Table 1.
2. Data and methodologies
2.1. Data
The present evaluation is based on the data on ferric sodium EDTA in a newly submitted dossier by
the applicant (Documentation provided to EFSA n. 1) and on the additional information that was
sought from the applicant during the assessment process (Documentation provided to EFSA n. 2,
Documentation provided to EFSA n. 3).
2.2. Methodologies
The assessment was conducted in line with the principles described in the EFSA Guidance on
transparency in the scientiﬁc aspects of risk assessment (EFSA, 2009) and following the relevant
existing Guidance from the EFSA Scientiﬁc Committee.
The ANS Panel assessed the safety of ferric sodium EDTA in line with the principles contained in the
latest existing guidance on the safety evaluation of food additives, namely the Guidance for submission
for food additive evaluations in 2012 (EFSA ANS Panel, 2012).
The evaluation of bioavailability of the nutrient (iron) from the source ferric sodium EDTA was
conducted in line with the principles contained in the ‘Guidance on submissions for safety evaluation of
nutrients or of other ingredients proposed for use in the manufacture of foods’ (SCF, 2001).
Dietary exposure to ferric sodium EDTA from the intended use as a source of iron added to food
and the relative iron intake derived from this intended use was estimated using the food consumption
data available within the EFSA Comprehensive European Food Consumption Database (EFSA, 2011a).
Table 1: Summary of dietary reference values for iron
Age Average requirement (mg/day) Population reference Intake (mg/day)
7–11 months 8 11
1–6 years 5 7
7–11 years 8 11
12–17 years (M) 8 11
12–17 years (F) 7 13
≥ 18 years (M) 6 11
≥ 18 years (F)
Premenopausal
Postmenopausal
7
6
16(a)
11
Pregnancy As for non-pregnant premenopausal women As for non-pregnant premenopausal women
Lactation As for non-lactating premenopausal women As for non-lactating premenopausal women
F, females; M, males.
(a): The PRI covers the requirement of approximately 95% of premenopausal women.
Ferric sodium EDTA
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3. Assessment
3.1. Technical data
3.1.1. Identity of the substance
According to the applicant, Ferrazone® and Ferrazone XF® are the trihydrate form of ferric sodium
EDTA with CAS Number 18154-32-0. The anhydrous form of ferric sodium EDTA has the CAS number
15708-41-5 and the EINECS number 239-802-2 (Documentation provided to EFSA n. 1).
The molecular formula of the trihydrate form is C10H12N2O8FeNa  3H2O and it has a molecular
weight of 421.1 g/mol; the molecular weight of the anhydrous form is 367.047 g/mol.
The structural formula for the trihydrate form is shown in Figure 1.
The chemical names provided by the applicant are the followings:
Ferrate(1-), [[N,N’-1,2-ethanediylbis[N-[(carboxy-kO)methyl]glycinato-kN,kO]] (4)]-, sodium, (OC-6-
21) and ferrate(1-), [[N,N’-1,2-ethanediylbis[N-(carboxymethyl)glycinato]](4-)-N,N’,O,O’,ON,ON’]-,
sodium, (OC-6-21).
The synonyms provided by the applicant for ferric sodium EDTA are the following:
Ferrate(1-), [(ethylenedinitrilo)tetraacetato]-, sodium; Ferric ethylenediaminetetraacetic acid, sodium
salt; Ferric sodium edetate; Ferric sodium ethylenediaminetetraacetate; Iron EDTA; Iron monosodium
EDTA; Iron sodium ethylenediaminetetraacetate; Iron sodium ethylenediaminetetraacetate (1:1:1);
Monosodium ferric EDTA; Sodium (ethylenediaminetetraacetato)ferrate(1-); Sodium [(ethylenedinitrilo)
tetraacetato]ferrate(III); Sodium (N,N,N’,N’-ethylenediaminetetraacetato)ferrate(1-); Sodium feredetate;
Sodium ferric EDTA; Sodium ferric ethylenediaminetetraacetate; Sodium iron EDTA; Sodium iron(III)
EDTA; Sodium iron(III) ethylenediaminetetraacetate; Sodium [(ethylenedinitrilo)tetraacetatato]ferrate
(III); Sodium [(ethylenedinitrilo)tetraacetato]ferrate(III).
3.1.2. Speciﬁcations
The applicant is proposing to update the current speciﬁcations for ferric sodium EDTA
(Documentation provided to EFSA n. 1) (Table 2).
Figure 1: Structural formula of the novel food ingredient ferric sodium EDTA trihydrate according to
Commission Decision 2010/331/EU
Table 2: Current speciﬁcations for ferric sodium EDTA as laid down in Annex 1 of Commission
Decision of 14 June 2010(a) and proposed changes by the applicant
Parameter Current speciﬁcation New proposed speciﬁcations
Appearance Yellow to brown powder Light-yellow to yellow-brown powder
Odour Odourless Odourless
pH (in 1% solution) 3.5–5.5 4.5–5.5
Iron (%) 12.5–13.5 13–13.5
Sodium (%) 5.5 NA
Water (%) 12.8 NA
Organic matter (CHNO) (%) 68.4 NA
Ferric sodium EDTA
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While at the time of the previous EFSA opinion on ferric sodium EDTA (EFSA ANS Panel, 2010), the
assessment focussed on Ferrazone®, which at the time was the only ferric sodium EDTA product
produced by the applicant, the applicant now commercialises also a second product, Ferrazone XF®,
which has a ﬁner consistency due to an extra grinding step in the manufacturing process. The updated
speciﬁcations are intended to be applicable to both products. The Panel however noted that the
proposed update to the speciﬁcations did not contain any information on the particle size of either
Ferrazone® or Ferrazone XF®.
To demonstrate compliance with the proposed speciﬁcations, the applicant provided analytical data
of three independent batches of Ferrazone XF® (Documentation provided to EFSA n. 1). All the
analyses were carried out according to respective methods described in the Food Chemical Codex. The
Panel noted that for one proposed parameter (identiﬁcation by IR) the applicant did not provide
supporting analytical information to demonstrate that the product Ferrazone XF® complies with the
proposed speciﬁcations.
To demonstrate microbiological safety the applicant provided microbiological analysis of ﬁve batches
of ferric sodium EDTA complying with ISO standards (Documentation provided to EFSA n. 1).
The Panel noted that no information on the solubility of the material was mentioned in either the
current or the proposed revised speciﬁcations, despite the applicant has stated that both Ferrazone® and
Ferrazone XF® have a solubility in water of 90 g/L at 20°C (Documentation provided to EFSA n. 3). The
Panel noted that according to the applicant, there is no difference in the solubility in water of the two
materials.
3.1.2.1. Particle size
Upon request from EFSA, the applicant provided information on particle size distribution for three
commercial batches of Ferrazone XF® obtained by laser diffraction (Documentation provided to EFSA
n. 3). The information provided indicated that the particle size corresponding to 10% of the cumulative
undersize distribution by volume was around 3 lm. However, the Panel noted that the data provided
did not follow the recommendation from the EFSA Guidance on risk assessment of the application of
nanoscience and nanotechnologies in the food and feed (EFSA Scientiﬁc Committee, 2011, 2018)
where information on particle size, number based size distribution and mass based size distribution of
the material is requested to be measured by more than one independent technique, one being
electron microscopy (EM) and if EM cannot be applied, the use of a different imaging technique is
suggested. Therefore, based on the information provided, the Panel cannot exclude the presence of
particles of ferric sodium EDTA in the nano range in Ferrazone XF® in the solid form.
3.1.3. Manufacturing process
The applicant provided description of the manufacturing process for the novel food ingredient. The
product under assessment is obtained by crystallisation following the addition of an aqueous solution
of FeCl3 to an aqueous solution of tetrasodium EDTA (Documentation provided to EFSA n. 1).
Parameter Current speciﬁcation New proposed speciﬁcations
EDTA (%) 65.5–70.5 67.5–71.5
Water-insoluble matter (%) Not more than 0.1 ≤ 1
Nitrilo-triacetic acid (%) Not more than 0.1 < 1
Identiﬁcation by IR NA –
Arsenic (mg/kg) NA ≤ 1
Lead (mg/kg) NA ≤ 1
Chloride (mg/kg) NA ≤ 600
Loss on drying (%) NA 12.5–13.5
Sulfate (%) NA ≤ 0.06
Free iron (%) NA ≤ 0.05
Absorbance (AU) NA ≤ 0.24
AU: absorbance unit; NA: not applicable.
(a): Commission Decision of 14 June 2010 authorising the placing on the market of Ferric Sodium EDTA as a novel food
ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council.
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The Panel noted that, compared to the assessment performed in the previous evaluation (EFSA
ANS Panel, 2010), the applicant is now commercialising also another ferric sodium EDTA product,
Ferrazone XF®, which is produced by adding an extra grinding step in the manufacturing process for
Ferrazone®, which results in a product with ﬁner consistency. The Panel however noted that in the
proposed speciﬁcations for ferric sodium EDTA, particle size is not listed as a parameter to characterise
the material and to discriminate between Ferrazone® and Ferrazone XF®.
3.1.4. Methods of analysis in food
The applicant provided reference to the Food Chemical Codex for the analytical methods used to verify
that the batches conformed to the proposed speciﬁcations. (Documentation provided to EFSA n. 1).
The Panel noted that no methods for the analysis of ferric sodium EDTA in the food were provided.
3.1.5. Stability of the substance and reaction and fate in food
For the stability of ferric sodium EDTA, the applicant refers to the previous EFSA opinion (EFSA ANS
Panel, 2010) and did not provide any new information.
The Panel noted that no information was provided on whether the extra grinding step applied to
produce Ferrazone XF® has an impact on the stability of the ﬁnal product.
3.2. Proposed uses and use levels
The applicant proposes to revise the current maximum amounts of ferric sodium EDTA authorised
in fortiﬁed foods, food supplements, foods for special medical purposes and total diet replacement for
weight control; the applicant is also requesting the extension of use of ferric sodium EDTA to
processed cereal-based foods and baby foods. According to the applicant, the intake of iron derived
from the currently authorised uses of ferric sodium EDTA would be equal to 16% of the PRI
established by EFSA for iron in infants.
3.2.1. Use in foods for the general population according to Regulation (EC) No
1925/2006
The applicant proposes to increase the current maximum amount of ferric sodium EDTA, expressed
as anhydrous EDTA, authorised in fortiﬁed foods under Regulation (EC) No 1925/2006, i.e. 12 mg
EDTA per 100 g of ﬁnal food. The proposed uses and use levels for ferric sodium EDTA in fortiﬁed
foods are reported in Table 3 (Documentation provided to EFSA n. 2).
Table 3: Current maximum amounts of ferric sodium EDTA and proposed uses and use levels for
ferric sodium EDTA, and corresponding iron levels
Food
category
number
Food category name
Proposed use levels (mg/kg) of
ferric sodium EDTA expressed as
I) ferric sodium EDTA trihydrate
II) ferric sodium EDTA (anhydrous)
III) EDTA
I/II/III
Corresponding
level of iron
(mg/kg)
Current maximum amounts(a)
Not
speciﬁed
Fortiﬁed foods according to Reg
(EC) 1925/2006
120(b) 23
Proposed uses and use levels
1 Dairy products and analogues
1.1 Unﬂavoured pasteurised and
sterilised (including UHT) milk
350/300/240 46
1.2 Unﬂavoured fermented milk
products, including natural
unﬂavoured buttermilk (excluding
sterilised buttermilk) non heat
treated after fermentation
350/300/240 46
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Food
category
number
Food category name
Proposed use levels (mg/kg) of
ferric sodium EDTA expressed as
I) ferric sodium EDTA trihydrate
II) ferric sodium EDTA (anhydrous)
III) EDTA
I/II/III
Corresponding
level of iron
(mg/kg)
1.3 Unﬂavoured fermented products,
heat-treated after fermentation
350/300/240 46
1.4 Flavoured fermented milk products
including heat treated products
350/300/240 46
3 Edible ices
3 Edible ices 350/300/240 46
4 Fruit and vegetables
4.2 Processed fruit and vegetables 350/300/240 46
6 Cereals and cereal products
6.1 Whole, broken, or ﬂaked grain 350/300/240 46
6.2 Flours and other milled products
and starches
450/390/310 60
6.3 Breakfast cereals 1150/1000/800 150
6.4 Pasta 350/300/240 46
6.5 Noodles 350/300/240 46
6.6 Batters 350/300/240 46
6.7 Pre-cooked or processed cereals 350/300/240 46
7 Bakery wares
7.1 Bread and rolls 350/300/240 46
7.2 Fine bakery wares 350/300/240 46
10 Eggs and egg products
10.2 Processed eggs and egg products 350/300/240 46
12 Salts, spices, soups, sauces,
salads and protein products
12.5 Soups and broths 350/300/240 46
12.6 Sauces 350/300/240 46
12.7 Salads and savoury based sandwich
spreads
350/300/240 46
12.8 Yeast and yeast products 350/300/240 46
12.9 Protein products, excluding products
covered in category 1.8
350/300/240 46
13 Foods intended for
particular nutritional uses as
deﬁned by Directive
2009/39/EC
13.4 Foods suitable for people intolerant
to gluten
350/300/240 46
14 Beverages
14.1 Non-alcoholic beverages 175/150/120 23
15 Ready-to-eat savouries
and snacks
15.1 Potato-, cereal-, ﬂour- or starch-
based snacks
350/300/240 46
15.2 Processed nuts 350/300/240 46
16 Desserts excluding products
covered in category 1, 3 and 4
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3.2.2. Use in food supplements according to Directive 2002/46/EC
Currently, ferric sodium EDTA, expressed as anhydrous EDTA, is allowed for use in food
supplements at doses up to 18 and 75 mg EDTA/day for children and adults respectively. The applicant
is proposing a single dose of ferric sodium EDTA up to 75 mg EDTA/day for both adults and children,
corresponding to intake levels of iron from food supplements up to 14 mg/day.
3.2.3. Use in foods for speciﬁc groups (FSG) according to Commission
Regulation (EU) No 609/2013
Currently, ferric sodium EDTA, expressed as anhydrous EDTA, is allowed for use in foods for special
medical purposes and total diet replacement for weight control at maximum amounts of 12 mg EDTA/
100 g of ﬁnal food.
The applicant proposed changes to increase the current maximum amount of ferric sodium EDTA,
expressed as anhydrous EDTA, allowed in foods for special medical purposes and total diet
replacement for weight control to 24 mg EDTA per 100 g of ﬁnal food or per individual serving of ﬁnal
food, when (according to the label) smaller than 100 g. The applicant also requested to extend the
authorisation to also include processed cereal-based foods and baby foods at the same proposed use
levels. With the new maximum amounts of ferric sodium EDTA proposed by the applicant, the
corresponding levels of iron from FSG would be up to 4.6 mg per 100 g of ﬁnal product. The proposed
use levels for ferric sodium EDTA in FSG and the corresponding level of iron are reported in Table 4
(Documentation provided to EFSA n. 2).
Food
category
number
Food category name
Proposed use levels (mg/kg) of
ferric sodium EDTA expressed as
I) ferric sodium EDTA trihydrate
II) ferric sodium EDTA (anhydrous)
III) EDTA
I/II/III
Corresponding
level of iron
(mg/kg)
16 Desserts excluding products covered
in category 1, 3 and 4
350/300/240 46
18 Processed foods not covered
by categories 1 to 17,
excluding foods for infants
and young children
18 Processed foods not covered by
categories 1 to 17, excluding foods
for infants and young children
350/300/240 46
EDTA: ethylenediaminetetraacetic acid.
(a): Commission Decision of 14 June 2010 authorising the placing on the market of Ferric Sodium EDTA as a novel food
ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council.
(b): Expressed as anhydrous EDTA.
Table 4: Current maximum amounts of ferric sodium EDTA and proposed changes to uses and use
levels for ferric sodium EDTA in FSG and corresponding iron levels
Food
category
number
Food category name
Proposed use levels (mg/kg) of
ferric sodium EDTA expressed as
I) ferric sodium EDTA trihydrate
II) ferric sodium EDTA (anhydrous)
III) EDTA
I/II/III
Corresponding
level of iron
(mg/kg)
Current authorised uses(a)
– Foods for special medical purposes 120(b) 23
– Total diet replacement for weight
control
120(b) 23
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3.3. Exposure estimate
3.3.1. Food consumption data used for exposure assessment
EFSA Comprehensive European Food Consumption Database
Since 2010, the EFSA Comprehensive European Food Consumption Database (Comprehensive
Database) has been populated with national data on food consumption at a detailed level. Competent
authorities in the European countries provide EFSA with data on the level of food consumption by the
individual consumer from the most recent national dietary survey in their country (EFSA, 2011a). New
consumption surveys added in the Comprehensive database were also taken into account in this
assessment.
The food consumption data gathered by EFSA were collected by different methodologies and thus
direct country-to-country comparisons should be interpreted with caution. Depending on the food
category and the level of detail used for exposure calculations, uncertainties could be introduced owing
to possible subjects’ underreporting and/or misreporting of the consumption amounts. Nevertheless,
the EFSA Comprehensive Database represents the best available source of food consumption data
across Europe at present.
Food consumption data from the following population groups: infants, toddlers, children,
adolescents, adults and the elderly were used for the exposure assessment. For the present
assessment, food consumption data were available from 33 different dietary surveys carried out in 19
European countries (Table 5).
Food
category
number
Food category name
Proposed use levels (mg/kg) of
ferric sodium EDTA expressed as
I) ferric sodium EDTA trihydrate
II) ferric sodium EDTA (anhydrous)
III) EDTA
I/II/III
Corresponding
level of iron
(mg/kg)
Proposed new uses
13 Foods intended for
particularnutritional uses
as deﬁned by Directive
2009/39/EC
13.1.3 Processed cereal-based foods and
baby foods for infants and young
children as deﬁned by Directive
2006/125/EC
350/300/240 46
13.2 Dietary foods for special medical
purposes deﬁned in Directive 1999/
21/EC (excluding products from
food category 13.1.5)
350/300/240 46
13.3 Dietary foods for weight control
diets intended to replace total daily
food intake or an individual meal
(the whole or part of the total daily
diet)
350/300/240 46
EDTA: ethylenediaminetetraacetic acid.
(a): Regulation (EU) No 609/2013 of the European Parliament and of the Council of 12 June 2013 on food intended for infants
and young children, food for special medical purposes, and total diet replacement for weight control and repealing Council
Directive 92/52/EEC, Commission Directives 96/8/EC, 1999/21/EC, 2006/125/EC and 2006/141/EC, Directive 2009/39/EC of
the European Parliament and of the Council and Commission Regulations (EC) No 41/2009 and (EC) No 953/2009.
(b): Expressed as anhydrous EDTA.
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Consumption records were codiﬁed according to the FoodEx classiﬁcation system (EFSA, 2011b).
Nomenclature from the FoodEx classiﬁcation system has been linked to the food categorisation system
(FCS) as presented in Annex II of Regulation (EC) No 1333/2008, part D, to perform exposure
estimates. In practice, the FoodEx food codes were matched to the FCS food categories.
3.3.2. Exposure to ferric sodium EDTA from its proposed uses
The previous EFSA opinion on ferric sodium EDTA (EFSA ANS Panel, 2010), concluded that if ferric
sodium EDTA was consumed from all three of the intended sources (PARNUTS, fortiﬁed foods and
supplements), the combined mean and 95th percentile EDTA intakes would be 8.6 and 9.5 mg/kg bw
per day, respectively, for children and 4.2 and 4.8 mg/kg bw per day, respectively, for adults at the
95th percentile. The Panel noted that this would exceed the ADI established by JECFA for calcium
disodium EDTA of 2.5 mg/kg bw per day (1.9 mg EDTA/kg bw per day) (JECFA, 2007). The Panel also
noted that when ferric sodium EDTA is used in PARNUTS or food supplements at levels which provide
22.3 mg iron/day for an adult and 11.1 mg iron/day for a child, the corresponding exposure to EDTA
would be 1.9 mg EDTA/kg bw per day for adults and 3.9 mg EDTA/kg bw per day for children.
Estimate of exposure based on the Food Additives Intake Model (FAIM) template
The applicant did not provide an estimate of the exposure to ferric sodium EDTA in the context of the
present dossier. The Panel therefore decided to perform a new estimate exposure using the FAIM tool
(version 2, June 2018). For the estimation of the exposure, the Panel considered the uses proposed by
the applicant (Documentation provided to EFSA n. 2) and reported in Sections 3.2.1, 3.2.2 and 3.2.3,
with the exceptions listed below because data were not available in the FAIM tool for the following food
categories: 1.3 – Unﬂavoured fermented products, heat-treated after fermentation; 6.6 – Batters; 6.7 –
Pre-cooked or processed cereals; and 13.4 - Foods suitable for people intolerant to gluten.
The food category 13.1 as proposed by the applicant (Documentation provided to EFSA n. 2) was
interpreted as referring to 13.1.3 – Processed cereal-based foods and baby foods for infants and
young children as deﬁned by Directive 2006/125/EC, which was not included in the table of proposed
uses provided by the applicant, but is part of the extension of use requested.
For the food category 14.1 - Non-alcoholic beverages, in the absence of further speciﬁcations from
the applicant it was assumed that the proposed uses included the corresponding subcategories
14.1.2.1, 14.1.2.2, 14.1.3, 14.1.4.1, 14.1.4.2, 14.1.5, and would exclude water as deﬁned in
subcategory 14.1.1.
Table 5: Population groups considered for the exposure estimates of ferric sodium EDTA
Population Age range
Countries with food consumption surveys
covering more than 1 day
Infants From more than 12 weeks up to and
including 11 months of age
Bulgaria, Denmark, Finland(b), Germany(b), Italy(b),
UK(b)
Toddlers From 12 months up to and including 35
months of age
Belgium, Bulgaria, Denmark, Finland(b), Germany(b),
Italy(b), Netherlands, Spain, UK(b)
Children(a) From 36 months up to and including 9
years of age
Austria, Belgium, Bulgaria, Czech Republic, Denmark,
Finland(b), France(b), Germany(b), Greece, Italy(b),
Latvia, Netherlands(b), Spain, Sweden, UK(b)
Adolescents From 10 years up to and including 17
years of age
Austria, Belgium, Cyprus, Czech Republic, Denmark,
Finland(b), France(b), Germany(b), Italy(b), Latvia(b),
Netherlands(b), Spain, Sweden(b), UK(b)
Adults From 18 years up to and including 64
years of age
Austria, Belgium, Czech Republic, Denmark, Finland(b),
France(b), Germany, Hungary, Ireland(b), Italy(b),
Latvia(b), Netherlands(b), Romania, Spain, Sweden(b),
UK(b)
The elderly(a) From 65 years of age and Older Austria, Belgium, Denmark, Finland(b), France(b),
Germany, Hungary, Ireland(b), Italy(b), Netherlands(b),
Romania, Sweden(b), UK(b)
(a): The terms ‘children’ and ‘the elderly’ correspond, respectively, to ‘other children’ and the merge of ‘elderly’ and ‘very elderly’
in the Guidance of EFSA on the ‘Use of the EFSA Comprehensive European Food Consumption Database in Exposure
Assessment’ (EFSA, 2011a).
(b): Dietary surveys considered by the NDA Panel in its opinion on Dietary Reference Values for iron (EFSA NDA Panel, 2015).
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Considering that the food category 18 (Processed foods not covered by categories 1–17, excluding
foods for infants and young children) is extremely unspeciﬁc (e.g. composite foods), processed foods,
prepared or composite dishes belonging to the food category 18 were reclassiﬁed under food
categories in accordance to their main component. Therefore, food category 18, although included in
the list of proposed uses by the applicant is not taken into account as contributor to the total exposure
estimates.
The results of the estimated intake of iron and exposure to EDTA calculated from the proposed
uses of ferric sodium EDTA are reported in Table 6.
The Panel noted that the estimated ranges of combined exposure to EDTA from the uses and
use levels of ferric sodium EDTA proposed by the applicant (Table 6, row H) will exceed the
current ADI established for EDTA (1.9 mg/kg bw per day) in all population groups at the mean
and 95th percentile.
The Panel further noted that, with respect to the proposed extension of use to include Processed
cereal based foods and baby foods, the estimated ranges of exposure to EDTA from this source would
be 1.2–8.5 mg/kg bw per day for infants and 0.2–1.4 mg/kg bw per day for toddlers (Table 6, row I).
Table 7 reports the main food categories contributing to total exposure to EDTA and iron intake
from the proposed uses of ferric sodium EDTA.
Table 6: Summary of anticipated intake of iron and exposure to EDTA from the proposed uses of
ferric sodium EDTA. Between brackets: number of surveys
Estimated
exposure
Infants
(4–11
months)
Toddlers
(12–35
months)
Children
(3–9 years)
Adolescents
(10–17
years)
Adults
(18–64
years)
The elderly
(≥ 65 years)
A. Dietary intake of iron (EFSA NDA Panel, 2015)(a) (mg/day)
2.6–6.0 (4) 5.0–7.0 (5) 7.5–11.5 (7) 9.2–14.7 (7) 9.4–17.9 (8) 9.4–17.9 (8)
B. Population reference intake for iron (EFSA NDA Panel, 2015)(a) (mg/day)
11 7 11 13(F) 11(M) 11–16(F)(b)
11(M)
11(F)
11(M)
C. Estimated iron intake from ferric sodium EDTA in fortiﬁed foods, and foods for speciﬁc groups
(mg/day)(c)
Mean 3.5–18 (6) 23.2–35.9 (10) 28.9–54.3 (18) 24.9–73.2 (17) 24.3–60.4 (17) 26.6–61.3 (14)
D. Estimated iron intake from ferric sodium EDTA in food supplements (mg/day)
– – 14 14 14 14
E. Estimated combined iron intake from all proposed uses of ferric sodium EDTA (mg/day)
Mean 3.5–18 23.2–35.9 42.9–68.3 38.9–87.2 38.3–74.4 40.6–75.3
F. Estimated exposure to EDTA from ferric sodium EDTA in fortiﬁed foods, and foods for speciﬁc
groups (mg/kg bw per day)
Mean 3.7–18.8 (6) 10.1–15.6 (10) 6.5–12.3 (18) 3.0–6.2 (17) 1.8–4.5 (17) 2.0–4.6 (14)
High-level
(P95)
8.1–23.3 (5) 17.7–26.0 (7) 11.0–19.4 (18) 4.6–10.3 (17) 3.3–8.1 (17) 3.5–8.8 (14)
G. Estimated exposure to EDTA from ferric sodium EDTA in food supplements (mg/kg bw per day)
– – 3 1–2 1 1
H. Estimated combined exposure to EDTA from all proposed uses of ferric sodium EDTA (mg/kg bw
per day)
Mean 3.7–18.8 10.1–15.6 9.5–15.3 4.0–8.2 2.8–5.5 3.0–5.6
High-level
(P95)
8.1–23.3 17.7–26.0 14.0–22.4 5.6–12.3 4.3–9.1 4.5–9.8
I. Estimated exposure to EDTA from [13.1.3] Processed cereal-based foods and baby foods (mg/kg
bw per day)
Mean 1.2–8.5 (5) 0.2–1.4 (8) – – – –
EDTA: ethylenediaminetetraacetic acid; M: male; F: female; bw: body weight.
(a): Although the classiﬁcation into age groups used by the NDA Panel in its 2015 opinion was slightly different from the one
used by the ANS Panel, it was assumed that estimates of iron intake would still be comparable. The following age groups
were used by the NDA Panel: < 1 year; 1 to < 3 years; 3 to < 10 years; 10 to < 18 years; > 18 years.
(b): For detail on women’s Population Reference Intake values, refer to Table 1.
(c): Calculated using default body weights as deﬁned by the EFSA Scientiﬁc committee (2012).
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Table 7: Main food categories contributing to total exposure to EDTA and iron intake calculated
from the proposed use levels of ferric sodium EDTA in fortiﬁed foods, and FSG, across
dietary surveys using FAIM (version 2). Results are shown as range of contribution (%)
and number of surveys (> 5% to the total mean exposure)
Food
category
number
Food category
name
Infants
(4–11
months)
Toddlers
(12–35
months)
Children
(3–9
years)
Adolescents
(10–17
years)
Adults
(18–64
years)
The elderly
(≥65
years)
1.1 Unﬂavoured
pasteurised and
sterilised (including
UHT) milk
7.4–68.0 (6) 14–50.6
(10)
10.3–52.1
(18)
7.2–45.8 (17) 7.6–42.0
(15)
5.8–22.2
(14)
1.2 Unﬂavoured
fermented milk
products, including
natural unﬂavoured
buttermilk (excluding
sterilised buttermilk)
non heat treated
after fermentation
36.1 (1) 5.3–30.1
(2)
19.2 (1) 5.3 (1) 5.2–6.2
(3)
5.9–7.9 (5)
1.4 Flavoured fermented
milk products
including heat
treated products
5.3 (1) 5.8–13.6
(5)
7.8–15.2
(8)
5.9–7.1 (5) 5.3 (1) –
4.2 Processed fruit and
vegetables
12.7–38.8 (3) 6.2–13.6
(9)
7.3–16.7
(14)
5.6–16.3 (14) 5.4–18.3
(15)
6.0–19.8
(14)
6.1 Whole, broken, or
ﬂaked grain
– – 5.6 (1) – – –
6.2 Flours and other
milled products and
starches
13.8 (1) 6.7 (1) 7.7 (1) 5.6–10.2 (3) 5.4–7.5
(4)
7.4 (1)
6.3 Breakfast cereals 8.7–21.5 (4) 7.0–14.9
(5)
6.0–10.6
(8)
5.2–8.5 (7) 7.3–17.2
(3)
5.6–29.2 (4)
6.4 Pasta – 6.7 (1) 6.9–9.0 (2) 8.2–8.4 (2) 8.7 (1) 9.2 (1)
7.1 Bread and rolls 8.2 (1) 5.1–11.9
(6)
5.7–16.0
(17)
7.3–17.3 (16) 6.9–21.7
(17)
5.9–22.1
(14)
7.2 Fine bakery wares – 8.7 (1) 5.1–11.4
(14)
5.6–10.9 (14) 5.7–9.5
(10)
5.3–10.5 (7)
12.5 Soups and broths – 7.7 (1) 6.5–14.1
(2)
5.7–12.5 (2) 7.1–13.6
(3)
6.0–14.4 (5)
12.7 Salads and savoury
based sandwich
spreads
– – – – 5.7–6.1
(2)
–
13.1.3 Processed cereal-
based foods and
baby foods for
infants and young
children as deﬁned
by Directive 2006/
125/EC
13.1–65 (5) 5.2–11.4
(4)
– – – –
14.1.2.1 Fruit juices as
deﬁned by Directive
2001/112/EC
5.1 (1) 6.2–11.4
(5)
5.1–12.0
(13)
5.2–16.0 (11) 5.6–10.0
(2)
6.4 (1)
14.1.4.1 Flavoured drinks with
sugar
– 5.5–11.6
(3)
5.3–14.7
(13)
5.2 -20.1 (15) 5.4–11.5
(10)
6.8 (1)
14.1.4.2 Flavoured drinks with
sweetener
– – 7.2 (1) 8.0 (1) 5.1 (1) –
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The Panel noted that unﬂavoured pasteurised and sterilised (including UHT) milk [1.1] is one of the
major contributors in all the population groups. With lower contributions the same applies to
processed fruit and vegetables [4.2]. Unﬂavoured fermented milk products [1.2] are highly
contributing to the intake of EDTA in younger population groups; while breakfast cereals [6.3], bread
and rolls [7.1] and coffee, tea, herbal and fruit infusions, chicory [14.1.5] highly contribute to the
intake of EDTA in older population groups.
The Panel further noted that the contribution of processed cereal-based foods and baby foods
[13.1.3] from the proposed extension of use, would range from approximately 13% to 65% of the
total exposure to EDTA in infants and from 5 to 11% in toddlers.
3.3.2.1. Uncertainty analysis
Uncertainties in the exposure assessment of ferric sodium EDTA as a source of iron have been
introduced in the previous section. In accordance with the guidance provided in the EFSA opinion
related to uncertainties in dietary exposure assessment (EFSA, 2007), the sources of uncertainties
have been considered and summarised in Table 8.
Overall, the Panel considered that the uncertainties identiﬁed would, in general, result in an
overestimation of both the real exposure to ferric sodium EDTA from its proposed use as a source of
iron added for nutritional purposes to foods for the general population, food supplements and foods
for special medical purposes, total diet replacement for weight control and processed cereal-based
foods and baby foods, and to the total exposure to EDTA and iron intake from the proposed uses of
ferric sodium EDTA.
Food
category
number
Food category
name
Infants
(4–11
months)
Toddlers
(12–35
months)
Children
(3–9
years)
Adolescents
(10–17
years)
Adults
(18–64
years)
The elderly
(≥65
years)
14.1.5 Coffee, tea, herbal
and fruit infusions,
chicory; tea, herbal
and fruit infusions
and chicory extracts;
tea, plant, fruit and
cereal preparations
for infusions, as well
as mixes and instant
mixes of these
products
– 6.2 (1) 5.4–11.3
(5)
5.1–13.6 (6) 5.7–34.2
(16)
11.4–39.7
(14)
16 Desserts excluding
products covered in
category 1, 3 and 4
– 5.2 (1) – – – –
EDTA: ethylenediaminetetraacetic acid; FAIM: Food Additives Intake Model; FSG: foods for speciﬁc groups.
Table 8: Qualitative evaluation of inﬂuence of uncertainties on the dietary exposure estimate
Sources of uncertainties Direction(a)
Consumption data: different methodologies/representativeness/underreporting/misreporting/no
portion size standard
+/–
Use of data from food consumption surveys covering only a few days to estimate high
percentiles (95th) long-term (chronic) exposure
+
Food categories selected for the exposure assessment: exclusion of food categories due to
missing FoodEx linkage (5/out of 34 categories)
–
Proposed maximum level exposure assessment scenario: proposed use levels considered for all
items within the food category
+
(a): +, uncertainty with potential to cause overestimation of exposure; –, uncertainty with potential to cause underestimation of
exposure.
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3.4. Biological and toxicological data
The safety of ferric sodium EDTA as a source of iron and the bioavailability of iron from this source
have been previously evaluated by the ANS Panel (EFSA ANS Panel, 2010). The previous conclusions
on ferric sodium EDTA were reached by the Panel on the basis of the evaluation of its components and
in particular of the ADI for EDTA established by JECFA (JECFA, 2007).
In support to the present application, the applicant has not provided any new data generated with
ferric sodium EDTA but has submitted data from studies conducted on other EDTA salts.
Ferric sodium EDTA, like other EDTA-metal complexes, dissociates in the gut to iron and EDTA;
hence, the applicant deemed toxicological studies of other EDTA salts also relevant when considering
the safety of ferric sodium EDTA. The Panel agreed that data generated with other EDTA salts could
be considered relevant for the safety assessment of ferric sodium EDTA.
3.4.1. Absorption, distribution, metabolism and excretion (ADME)
3.4.1.1. Bioavailability of iron from ferric sodium EDTA
In its previous opinion (EFSA ANS Panel, 2010), the Panel noted that information on the
bioavailability of iron from ferric sodium EDTA based on iron fortiﬁcation studies in humans was
available. From those studies, the Panel deduced that iron was liberated from the complex and that it
was bioavailable despite the presence of inhibitory factors in the diet that might form insoluble
complexes with iron. The Panel also noted data indicating that iron in the form of ferric sodium EDTA
was two to three times more bioavailable than iron in the form of ferrous sulphate and that it was
efﬁciently incorporated into haemoglobin.
The Panel also noted that the absorption of iron from ferric sodium EDTA was regulated
physiologically by the body’s iron status, in a manner similar to that for other iron compounds and that
dietary iron fortiﬁcation with ferric sodium EDTA was not expected to result in iron overload in iron-
repleted individuals.
In 2010, the Panel reviewed a study of iron absorption from ferric sodium EDTA in pigs (Candela
et al., 1984) demonstrating that the iron in ferric sodium EDTA dissociates from the chelate and is
released into the luminal inorganic iron pool. The majority of the excreted iron was found in the
faeces, in an insoluble form, which was not identiﬁed by the authors. Less than 1% of ferric-EDTA
complex-ion and not more than 5% of the EDTA moiety was absorbed after dissociation from iron
(likely bound to other metals). The iron and the EDTA that were found in the faeces were not
associated with each other. The majority of the EDTA remained in the soluble pool, while the Fe was in
an insoluble fraction. The authors did not determine the nature of this iron. The authors reported that
the iron that was absorbed was incorporated into haemoglobin.
In the context of this application, the applicant has provided three new ﬁeld trials aimed at
demonstrating efﬁcacy of a food fortiﬁcation regimen with ferric sodium EDTA. All three studies were
controlled, double-blinded, randomised trials on children using different food vehicles fortiﬁed with
ferric sodium EDTA: porridge prepared with maize ﬂour supplemented with 28 or 56 mg iron/kg ﬂour
(Andang’o et al., 2007), chapattis prepared with wheat ﬂour supplemented with 60 mg iron/kg ﬂour
(Muthayya et al., 2012) and biscuits prepared with wheat ﬂour supplemented with 3.6 mg iron/biscuit
(Bouhouch et al., 2016) for a duration of 5–7 months. The Panel noted these new publications
provided by the applicant as part of the dossier and considered them as supporting evidence for the
bioavailability of iron from ferric sodium EDTA.
The Panel noted that no data on the potential difference in the bioavailability of Ferrazone® and
Ferrazone XF® were provided.
3.4.1.2. Studies with other EDTA salts
In addition to the studies previously evaluated by the Panel, the applicant has submitted further
information on the ADME of other EDTA salts.
In a rat study (Foreman et al., 1953), an oral dose of 50 mg/kg bw of 14C-labelled calcium
disodium EDTA was poorly absorbed in the gastrointestinal tract. Absorption after 24 h was between
2% and 4% with 80–95% of the dose appearing in the faeces within 24 h; absorption was still
apparent at 48 h. In animals given intraperitoneal injections, the EDTA was rapidly excreted in the
urine (85% by 1.5 h, 95% in 25 h). According to the authors in the stomach, the calcium-EDTA
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complex-ion dissociated at the low pH, which was subsequently followed by precipitation of the acid
form of EDTA and slow re-dissolution in the intestines.
Srbova and Teisinger (1957) injected 200 mg of calcium disodium EDTA into the duodenum of rats,
and 2 h later observed that the amount of complex not recovered ranged from 6.5% to 26%.
In support of the current application, the applicant has provided full study reports from two studies
(Yang, 1952; Chan, 1956), which were part of PhD theses and were available to the Panel only in
summary format at the time of the previous assessment of ferric sodium EDTA.
In rats fed disodium EDTA in the diet at levels of 0.5%, 1.0% or 5.0% (Yang, 1952), approximately
82.2%, 44.5% and 45.4% of the ingested EDTA, respectively, were excreted, primarily in faeces
(99.4%, 98.2% and 97.5%) and in small amounts in the urine.
Chan (1956) conducted a similar experiment, in which he observed that 32 h after a single dose of
95 mg disodium EDTA per rat administered by gavage, 93% of the EDTA was recovered from the
colon. After doses of 47.5, 95, and 142.5 mg disodium EDTA, the amount of EDTA recovered in the
urine was directly proportional to the dose given, suggesting that EDTA was absorbed from the
gastrointestinal tract by passive diffusion.
In a human study (Foreman and Trujillo, 1954), an administered dose of 1.5 mg of 14C-labelled
calcium disodium EDTA was absorbed to an extent of 5%.
In a human study in which a single dose of 3 g of calcium disodium EDTA was administered orally
(Srbova and Teisinger, 1957), only 2.5% of the complex was excreted in the urine.
3.4.2. Genotoxicity
In its previous assessment (EFSA ANS Panel, 2010), the Panel concluded that from the information
available at the time there was no safety concern with respect to genotoxicity of ferric sodium EDTA as
a source of iron added for nutritional purposes to food.
No further genotoxicity studies on ferric sodium EDTA were provided in the context of the present
application.
3.4.3. Acute toxicity
3.4.3.1. Studies on ferric sodium EDTA
In its previous opinion (EFSA ANS Panel, 2010), the Panel noted that ferric sodium EDTA has a low
acute oral toxicity with oral LD50 values of 2,710–10,000 mg/kg bw (equivalent to approximately 359–
1,326 mg iron/kg bw, respectively) in male and female Sprague–Dawley rats, and 794 mg/kg bw
(approximately 105 mg iron/kg bw) in male and female Kunming mice (Sichuan Provincial Sanitary and
Anti-epidemic Station, 1993; Whittaker et al., 2002).
3.4.3.2. Studies on other EDTA salts
In support of the present application, the applicant submitted additional information on acute
toxicity studies with other EDTA salts.
Based on the new information provided in the dossier, the Panel noted that also calcium disodium
EDTA was of low acute toxicity as the oral LD50 was reported to be 10,000 mg/kg bw in the rat (strain
and species not speciﬁed), 7,000 mg/kg bw in the rabbit (strain and species not speciﬁed) and 12,000
mg/kg bw in the dog (Oser et al., 1963).
Similarly, the acute oral toxicity of disodium EDTA was low as the reported LD50 was from 2,000 to
2,200 mg in the rat (strain and species not speciﬁed) (Yang, 1952) and 2,300 mg/kg bw in the rabbit
(Shibata, 1956).
3.4.4. Short-term and subchronic toxicity
3.4.4.1. Studies on ferric sodium EDTA
In its previous opinion (EFSA ANS Panel, 2010), the ANS Panel reviewed three subchronic studies in
rats with dietary exposure to ferric sodium EDTA.
One of these studies was a 90-day study by Sichuan Provincial Sanitary and Anti-epidemic Station
(1993) where the authors identiﬁed a no observed adverse effect level (NOAEL) of 160 mg ferric
sodium EDTA/kg bw per day.
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The second was a 90-day study where the dose tested amounted to 2,500 mg/kg bw per day (Su
et al., 1999). Based on the results, the ANS Panel had identiﬁed a NOAEL of 250 mg ferric sodium
EDTA/kg bw per day.
In the third study of 61 days in rats (Appel et al., 2001), a NOAEL of 84 mg ferric sodium EDTA/kg
bw per day was proposed by the authors. When expressed as iron, this NOAEL corresponded to 11.2
mg iron/kg bw per day. In its opinion (EFSA ANS Panel, 2010), the ANS Panel noted, that JECFA
concluded in 2000, based on this study, that administration of ferric sodium EDTA in the diet would not
result in a greater uptake of iron once nutritional requirements for iron were met (JECFA, 2007).
3.4.4.2. Studies on other EDTA salts
In addition to the studies previously evaluated, the applicant has submitted four other subchronic
studies, which were not available to the ANS Panel in 2010. The studies are summarised below.
Thirty-three albino rats were divided into ﬁve groups and received a standard rodent diet (Purina Fox
Chow) added with either 0 (group 1, 3 males and 5 females; and group 5, 1 males and 2 females), 0.5
(group 2, 3 males and 5 females), 1.0 (group 3, 3 males and 5 females) or 5% (group 4, 1 males and 5
females) of disodium EDTA8 (Yang, 1952, 1964) for 12 weeks. These doses were equivalent to 0, 250,
500 and 2,500 mg/kg bw per day of disodium EDTA. The author noted that the rats from groups 4 and 5
were littermates born from dams kept on diet added 0.5% disodium EDTA for 8 months. The only
parameters monitored were clinical conditions, body weight and feed intake. All animals survived to the
end of week 12. According to the authors, the only differences to controls were a continuing diarrhoea
and lower feed intake in the high-dose group. The Panel noted that male and female rats receiving 5%
of disodium EDTA had lower body weights than their littermates control (e.g. on day 84: for males 132 g
vs 300 g in the control and for females 133 g vs 180 g in the controls). The animals were not killed but
continued for a 2-year period as ‘a chronic toxicity experiment’ since, according to the author, the results
of this subchronic toxicity study did not show any marked toxic effect of the test substance (see
Section 3.4.5 for further description). Based on the limitations in the study design and reporting, the
Panel considered this study not suitable for risk assessment of ferric sodium EDTA.
In a second study, 50 weanling albino rats (Wistar, initial body weight of 50–70 g) of both sexes
were divided into ﬁve groups and received either a basal low mineral diet (control group, 7 males and
6 females) or this diet added 0.5% or 1% of disodium calcium EDTA (4 males and 4 females, and 6
males and 2 females, respectively) or 0.5% or 1% disodium EDTA9 (5 males and 6 females, and 4
males and 6 females, respectively) for 90 days (Chan, 1956, 1964). The only parameters monitored
were clinical conditions, body weight and feed intake. As reported by the author at the end of the
study period, body weights and feed intake in groups receiving 0.5% and 1% disodium calcium EDTA
were comparable to those in the control group. A slight increase in body weight was reported for the
0.5% disodium EDTA group. In the 1% disodium EDTA group, a slight decrease in body weight,
anaemic appearance and diarrhoea were reported. The author concluded that there was no apparent
toxicity in all test groups and the study therefore continued for 205 days (see below).
The rats from the above 90-day study continued on the respective diets up to 205 days (Chan, 1956,
1964). The survival was not different between the experimental and control groups. In the 1% disodium
EDTA group, animals appeared anaemic and manifested slight diarrhoea, while clinical appearance of
other test groups was similar to that of controls. The author considered that the diarrhoea was most
probably due ‘to the action of EDTA on the intestinal tract inﬂuencing its absorption and secretory
function’. Final body weight, body weight gain and feed intake of all test groups were not statistically
signiﬁcantly different from the controls. Statistical analyses of data from limited haematological and
clinical chemistry examinations demonstrated a decrease (p < 0.01) in erythrocyte and leucocyte counts,
increase (p < 0.01) in coagulation time and serum calcium content in males and females from the 1%
disodium EDTA group as compared to controls. Furthermore, erythrocyte count was decreased
(p < 0.05) and leucocyte count was increased (p < 0.01) in the 0.5% disodium calcium EDTA and 0.5%
disodium EDTA groups, and erythrocyte count was also decreased (p < 0.01) in 1% disodium EDTA
group. Histopathological examination which was limited to liver, kidney and spleen did not reveal any
appreciable differences between the treated and the control groups. The author noted, however,
sinusoid dilatation and slight increase in number of Kupffer cells in the livers and occasionally indistinct
appearance of tubules in the kidney in 1% disodium EDTA group as compared to controls. The author
8 Referred to as Sequestrene Na2 in the original PhD thesis.
9 Disodium calcium EDTA and disodium EDTA were referred to as Sequestrene Na2Ca and Sequestrene Na2 in the original PhD
thesis.
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considered that for both EDTA salts there was absence of adverse effects at 0.5% and 1%
concentrations in the diet. The Panel noted that feeding 1% disodium EDTA was associated with changes
in some haematological parameters and with slight osmotic diarrhoea, which is regarded as an
undesirable effect. The Panel further noted that the relevance of the study was limited because of the
low number of animals and the limited number of parameters measured.
The applicant also provided an additional toxicity study in the rat performed with disodium EDTA,8
which is a part of another PhD thesis work (Krum, 1948). Weanling male and female Wistar rats (mean
body weight 60 g) received either 0% (control, n = 6, number per sex not informed) or 0.5% (n = 9,
number per sex not informed) of disodium EDTA in the diet for 44 weeks. This dietary concentration
was equivalent to 250 mg disodium EDTA/kg bw per day or equal to 196 mg/kg bw per day based on
recorded feed intake. Body weight and feed intake (the only parameters monitored), were recorded
once weekly throughout the study and were not different between the groups. All animals survived to
the termination except one from the 0.5% group (sex not reported) which died in week 38 from
respiratory infection. The Panel noted that this study was performed on a low number of animals, with
one dose level, no haematology, clinical chemistry examinations or urinalysis were performed in the
study, the reporting was limited to body weight and feed intake and no pathology reporting was
included in the thesis. Based on the limitations in the study design and reporting, the Panel considered
this study not suitable for risk assessment of ferric sodium EDTA.
In a 12-month study, 16 mongrel dogs (6 months of age, 2 males and 2 females in the control and
1 male and 3 females in each of the test groups) received either a control diet (30 g ration/kg bw per
day) or the control diet supplemented with 50, 100 or 250 mg calcium disodium EDTA/kg bw per day
(equal to 58, 130 and 338 mg/kg bw per day) (Oser et al., 1963). No statistically signiﬁcant
differences were reported in body weight, clinical pathology parameters or organ weights between the
calcium disodium EDTA-treated groups and controls. No evidence of osteoporosis or other osseous
changes was reported and there were no notable macroscopic or microscopic changes.
3.4.5. Chronic toxicity and carcinogenicity
3.4.5.1. Studies on other EDTA salts
In its previous opinion (EFSA ANS Panel, 2010), the Panel noted that no chronic toxicity or
carcinogenicity studies had been conducted with ferric sodium EDTA; however, several studies were
presented that had been conducted with other EDTA salts such as trisodium EDTA (NCI, 1977),
calcium disodium EDTA (Oser et al., 1963) and disodium EDTA (Yang, 1964). From these studies, the
Panel concluded that EDTA salts do not raise concern with respect to carcinogenicity.
The applicant has now provided the full study report of a chronic toxicity study that was available
only in summary form at the time of the previous EFSA assessment of ferric sodium EDTA. The study
was a 2-year toxicity study in the rat with disodium EDTA, which was the follow up of the 12-week rats
study by Yang (1952, 1964) described in Section 3.4.4. The ﬁve groups of Wistar rats previously fed
0%, 0.5%, 1% or 5% of disodium EDTA in their diets for 12 weeks continued on their respective diets
for a total period of 2 years. The survival (based on combined mortality for males and females
reported by the author) was 37.5%, 62.5%, 75% and 100% in the control, 0.5%, 1% and 5% groups,
respectively. Pneumonia was reported as the cause of the death. According to the author, the body
weights of males and females in all treated groups were not statistically signiﬁcantly different from
those in the respective controls. Feed intake, erythrocyte counts and blood coagulation times
(recorded at the end of the study period), ash content of bones and histological examination of several
organs and tissues did not reveal any differences which could be attributed to treatment. The
Panel noted low number of animals per group (see Section 3.4.4) and that no information was given
on the clinical condition of the animals and whether the continuous diarrhoea in the 5% group
reported in the subchronic phase of the study was also present during the 2-year study period. With
regard to results on body weight the Panel noted that: (1) the data on mean body weight of control
males (group 1) were not available from week 88 to 104 because all males were dead (controls for
group exposed to 0.5% and 1% of the test compound), (2) the body weights of males and females
from 5% group tended to be lower than in their litter mate control (group 5) through whole
experimental period. The Panel considered this study not suitable for risk assessment of ferric sodium
EDTA because of the low number of animals and limited reporting.
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3.4.6. Reproduction and Developmental Toxicity
Reproductive toxicity studies with other EDTA salts
In its 2010 assessment, the Panel considered one dietary multigenerational study with calcium
disodium EDTA (Oser et al., 1963), and noted that no compound-related mortality, reproductive, or
teratogenic effects were reported. At the time, the Panel identiﬁed a NOAEL of 195 mg EDTA/kg bw
per day (EFSA ANS Panel, 2010).
In the context of the current dossier the applicant has provided a new reproductive toxicity study,
which was part of the PhD thesis from Yang (1952), assessed in Sections 3.4.4 and 3.4.5. Twenty-four
Wistar rats divided into four groups (2 males and 4 females each) were administered a control diet
supplemented with 0%, 0.5%, 1% and 5% disodium EDTA,8 respectively. Animals were mated at 100
days of age. In order to obtain second litters, mating was repeated 10 days after weaning of the ﬁrst
litters. The author reported that the tests did not give consistent results. The animals fed 5% disodium
EDTA in the diet did not produce any litters after 2 months of mating. However, the results of the
0.5% and 1% disodium EDTA groups were satisfactory in that the test animals all gave normal ﬁrst
and second litters. All litters were normal in size, growth, and health. The Panel considered the study
too limited due to the very low number of animals used per group and the very limited reporting and
therefore the Panel could draw no conclusions regarding reproductive toxicity effects.
Developmental toxicity studies with ferric sodium EDTA
In its previous opinion (EFSA ANS Panel, 2010), the Panel identiﬁed a NOAEL of 200 mg ferric
sodium EDTA trihydrate/kg bw per day for developmental effects from a prenatal developmental
toxicity study in rats (Sichuan Provincial Sanitary and Anti-epidemic Station, 1993). The ANS
Panel revisited the prenatal developmental study of the Sichuan Provincial Sanitary and Anti-epidemic
Station (1993) and noted that the study had limitations. It was unclear from the information available
whether the compound was given in the diet or by gavage. The Panel considered that the NOAEL of
the prenatal toxicity study should be 50 mg ferric sodium EDTA/kg bw per day (corresponding to 34.7
mg EDTA/kg bw per day). The Panel noted that this study cannot be used for risk assessment.
Developmental toxicity studies with other EDTA salts
In its previous opinion (EFSA ANS Panel, 2010), the Panel considered a developmental study
conducted with several EDTA salts (EDTA, disodium EDTA dehydrate, trisodium EDTA monohydrate,
calcium disodium EDTA dehydrate and tetrasodium EDTA dehydrate) (Schardein et al., 1981),
administered by gavage from gestation day 7 to 14 to CD rats. The Panel considered that the NOAEL
for developmental effects in this study was approximately 900 mg EDTA/kg bw per day.
3.5. Discussion
The present opinion deals with the evaluation of proposed changes to the current authorisation of
ferric sodium EDTA as a novel food ingredient used as a source of iron. Within the current application,
it is proposed to increase the maximum amounts of ferric sodium EDTA that can be added to foods for
the general population, food supplements in children, foods for special medical purposes and total diet
replacement for weight control. The applicant also proposed inclusion of ferric sodium EDTA in the list
of substances permitted for use in processed cereal-based foods and baby foods.
In the dossier submitted by the applicant in support of the current application, it was reported that
two different products are being commercialised as ferric sodium EDTA: Ferrazone®, which was the
subject of the previous evaluation by the ANS Panel (EFSA ANS Panel, 2010) and Ferrazone XF®, a
product of ﬁner consistency obtained by adding an extra grinding step to the manufacturing process of
Ferrazone®.
The applicant has submitted analytical results from three batches of Ferrazone XF® to demonstrate
compliance with the proposed update to the existing speciﬁcations.
The Panel however noted that no parameters have been proposed for the update of the
speciﬁcations of ferric sodium EDTA with respect to particle size which could be used for the
identiﬁcation of the two different products. Furthermore, based on the analytical data provided,
the Panel could not exclude the presence of particles of ferric sodium EDTA in the nano range in
Ferrazone XF® in the solid form.
The Panel further noted that according to the applicant, there was no difference in the solubility in
water of Ferrazone® and Ferrazone XF®.
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To support the proposed increase in the maximum amounts of ferric sodium EDTA in currently
authorised uses and to extend the use to processed cereals-based food and baby food, the applicant
proposed a revision of the current ADI for EDTA on the basis of newly submitted toxicological data on
other EDTA salts, previously not available for assessment by the Panel.
The Panel noted that the currently authorised amounts of ferric sodium EDTA have been set such that
the EDTA intake should not exceed the ADI of 1.9 mg/kg bw per day (EFSA ANS Panel, 2010). This ADI
for EDTA of 1.9 mg/kg bw per day, established by JECFA from the ADI for calcium disodium EDTA (E 385)
based on the study of Oser et al. (1963) (JECFA, 2007), was used by the ANS Panel in 2010.
Based on the additional studies provided and on the previous assessment (EFSA ANS Panel, 2010),
the Panel considered that following oral ingestion, ferric sodium EDTA would dissociate in the
gastrointestinal tract into its components, EDTA and iron. EDTA was not absorbed to a large extent
and was excreted in the faeces. Minor amounts of EDTA may be absorbed but are not metabolised,
and may be excreted unchanged in urine. Only a small proportion of the dissociated iron was
absorbed; the largest fraction was excreted in an insoluble form in the faeces.
The Panel further noted that the ADME studies assessed may be of limited relevance for the newly
proposed form of ferric sodium EDTA indicated by the applicant, i.e. Ferrazone XF®, since, due to its
reduced particle size, the product may have different characteristics with regard to ADME. With the
available data, the Panel was not in the position to draw conclusions on this matter.
In its previous opinion (EFSA ANS Panel, 2010), the ANS Panel reviewed three subchronic studies in
rats with dietary exposure to ferric sodium EDTA. In the present dossier the applicant submitted four
additional subchronic studies on EDTA salts other than ferric sodium EDTA. The Panel noted that the
design and reporting of some of these studies had limitations, and were not considered suitable for
risk assessment. The Panel further noted that these studies did not add any new relevant information
to the database available for the previous evaluation of ferric sodium EDTA (EFSA ANS Panel, 2010).
The Panel considered that the two reproductive toxicity studies submitted in the dossier (Yang, 1952;
Oser et al., 1963) provided insufﬁcient data to evaluate the reproductive toxicity of ferric sodium EDTA.
The Panel noted that the prenatal developmental study of the Sichuan Provincial Sanitary and Anti-
epidemic Station (1993) was inadequate for risk assessment, but is nevertheless concerned about the
effects of ferric sodium EDTA. The Panel was also concerned about the effects of EDTA given in the
diet seen in other, albeit limited, studies. The difference in adverse developmental effects following
different routes of administration (gavage vs dietary) were observed by Kimmel (1977). The effect in
the dietary studies may be caused by binding of other metal ions to EDTA (e.g. zinc). Zinc deﬁciency
can be the reason for the developmental effects (Hurley and Swenerton, 1971; Swenerton and Hurley,
1971). Furthermore, NOAELs of approximately 900 mg EDTA/kg bw per day were identiﬁed in prenatal
developmental studies in rats with various forms of EDTA (EDTA, disodium EDTA dehydrate, trisodium
EDTA monohydrate, calcium disodium EDTA dehydrate and tetrasodium EDTA dehydrate), when
administered by gavage from gestational day 7 to 14 (EFSA ANS Panel, 2010). The Panel noted that a
dietary prenatal developmental toxicity and a reproductive toxicity studies according to the current
OECD guidelines are required.
On the basis of the information provided in the current dossier, the Panel considered that there was
no sound scientiﬁc justiﬁcation to increase the current ADI for EDTA and change the previous
conclusion on ferric sodium EDTA.
The Panel has estimated intake levels for iron and exposure to EDTA resulting from the new
proposed uses and use levels. The Panel noted that the exposure to EDTA for all population groups
from the new proposed uses will signiﬁcantly exceed the current ADI of 1.9 mg/kg bw per day at the
mean and 95th percentile.
The Panel further noted that in accordance with Regulation (EU) No 257/2010, a full re-evaluation
of the safety of calcium disodium EDTA (E 385) as a food additive is to be performed by EFSA. In this
context, the full toxicological database for this substance will be reviewed including the basis for
establishing the ADI for EDTA. The Panel noted that additional toxicity studies will be needed for this
re-evaluation.
4. Conclusions
The Panel conﬁrmed that ferric sodium EDTA is a source from which iron is bioavailable.
In assessing the safety of the proposed revision to the existing speciﬁcations for the novel food
ingredient ferric sodium EDTA, the Panel noted that this would not discriminate between the previously
evaluated substance (marketed as Ferrazone®) and the one of ﬁner consistency (Ferrazone XF®)
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produced by adding an extra grinding step to the manufacturing process. In particular, the Panel noted
that particle size was not one of the proposed parameters for the revised speciﬁcations. The
Panel noted that it was not possible to determine whether particles of ferric sodium EDTA in the nano
range were present in solid Ferrazone XF®.
The Panel concluded that the exposure assessment based on the proposed extension of uses and
use levels would lead to the current ADI for EDTA being exceeded in all population groups at the mean
and 95th percentile.
Furthermore, the Panel concluded that the toxicological data submitted by the applicant did not add
any new relevant information to the database on which the current ADI was established.
Consequently, the Panel concluded that there was no basis to increase the ADI for EDTA and hence
increase the use levels of ferric sodium EDTA or introduce additional uses as proposed by the
applicant.
5. Recommendations
The Panel recommended that additional toxicological data should be provided to address the
shortcomings in the available toxicity database prior to the re-evaluation of calcium disodium EDTA
(E 385) as a food additive.
Documentation provided to EFSA
1) Dossier ‘Application to Amend Annexes I and II of the Commission Decision of 14 June 2010
Authorising the Placing on the Market of Ferric Sodium EDTA as a Novel Food Ingredient [Under
Regulation (EC) No 258/97 of the European Parliament and of the Council of 27th January 1997
Concerning Novel Foods and Novel Food Ingredients] and to Amend the Union List in the Annex
of Regulation (EU) No 609/2013 of 12 June 2013 on Food Intended for Infants and Young
Children, Food for Special Medical Purposes, and Total Diet Replacement for Weight Control’.
February 2014. Submitted by AkzoNobel Business Area Specialty Chemicals.
2) Additional data provided on 8 November 2017. Submitted by AkzoNobel Business Area
Specialty Chemicals in response to a request from EFSA.
3) Additional data provided on 10 April 2018. Submitted by AkzoNobel Business Area Specialty
Chemicals in response to a request from EFSA.
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Abbreviations
ADI acceptable daily intake
ADME absorption, distribution, metabolism and excretion
ANS Panel Panel on Food Additives and Nutrient Sources added to Food
AR average requirement
AU absorbance unit
BW body weight
CAS Chemical Abstracts Service
EDTA ethylenediaminetetraacetic acid
EINECS European List of Notiﬁed Chemical Substances
EM electron microscopy
FAIM Food additive intake model
FCS food categorisation system
FSG foods for speciﬁc groups
IR infrared radiation
JECFA Joint FAO/WHO Expert Committee on Food Additives
LD lethal dose
NDA Panel Panel on Dietetic Products, Nutrition and Allergies
NOAEL no observed adverse effect level
PARNUTS Foodstuffs intended for particular nutritional uses
PRI Population Reference Intake
SCF Scientiﬁc Committee on Food
UHT ultra-high temperature processing
UL Upper level
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